

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
02 September 2021 (02.09.2021)



(10) International Publication Number
WO 2021/170100 A1

(51) International Patent Classification:

C12N 15/09 (2006.01) A61P 35/00 (2006.01)

C07K 16/18 (2006.01)

EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/CN2021/078203

(22) International Filing Date:

26 February 2021 (26.02.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/CN2020/076937

27 February 2020 (27.02.2020) CN

Published:

— with international search report (Art. 21(3))

— with sequence listing part of description (Rule 5.2(a))

(71) Applicant: NANJING LEGEND BIOTECH CO., LTD.

[CN/CN]; No. 6 Building of Nanjing Life Science Town,
No. 568 Longmian Avenue, Jiangning District, Nanjing,
Jiangsu 211100 (CN).

(72) Inventors: FAN, Xiaohu; 1067 Armitage Crescent SW,

Edmonton, Alberta T6W 0K3 (CA). MAO, Jie; No. 6
Building of Nanjing Life Science Town, No. 568 Long-
mian Avenue, Jiangning District, Nanjing, Jiangsu 211100
(CN). ZHUANG, Qiuchuan; Room 104, 36th Building,
Yuecheng International Garden, No. 9, Huashen Street,
Yuhuatai District, Nanjing, Jiangsu 210012 (CN). WANG,
Ruixue; No. 6 Building of Nanjing Life Science Town, No.
568 Longmian Avenue, Jiangning District, Nanjing, Jiang-
su 211100 (CN).

(74) Agent: AFD CHINA INTELLECTUAL PROPERTY

LAW OFFICE; Tower B, 21st Fl., Suite 2108, 38 Xueqing
Road, Haidian, Beijing 100083 (CN).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,

(54) Title: ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS TARGETING GLYPICAN-3 (GPC3) AND METHODS OF USE THEREOF

(57) Abstract: Provided are anti-glypican-3 (GPC3) antibodies or antigen binding fragments thereof, and a chimeric antigen receptor (CAR) that binds glypican-3 (GPC3) containing an anti-GPC3 antibody in an extracellular domain, a transmembrane domain, and an intracellular signaling domain. Immune effector cells transduced with the disclosed CAR constructs can be used for cancer immunotherapy.



WO 2021/170100 A1